VBI Vaccines, Inc. – (NASDAQ:VBIV) has been assigned an average recommendation of “Hold” from the seven analysts that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $10.50.
Several brokerages have recently issued reports on VBIV. Zacks Investment Research raised VBI Vaccines from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a report on Saturday, December 23rd. Noble Financial reissued a “buy” rating on shares of VBI Vaccines in a report on Friday, March 23rd. Finally, BidaskClub cut VBI Vaccines from a “hold” rating to a “sell” rating in a report on Saturday, January 20th.
Several hedge funds have recently modified their holdings of VBIV. The Manufacturers Life Insurance Company acquired a new position in shares of VBI Vaccines in the 4th quarter valued at about $126,000. California State Teachers Retirement System acquired a new position in shares of VBI Vaccines in the 2nd quarter valued at about $167,000. Kamunting Street Capital Management L.P. increased its stake in shares of VBI Vaccines by 64.4% in the 4th quarter. Kamunting Street Capital Management L.P. now owns 49,308 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 19,308 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of VBI Vaccines by 36.0% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 58,200 shares of the biopharmaceutical company’s stock valued at $249,000 after purchasing an additional 15,400 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of VBI Vaccines by 54.2% in the 4th quarter. Bank of New York Mellon Corp now owns 68,478 shares of the biopharmaceutical company’s stock valued at $293,000 after purchasing an additional 24,072 shares in the last quarter. 48.33% of the stock is owned by institutional investors and hedge funds.
Shares of VBIV stock opened at $3.36 on Friday. The stock has a market capitalization of $223.47, a PE ratio of -4.36 and a beta of 2.04. The company has a quick ratio of 5.26, a current ratio of 5.32 and a debt-to-equity ratio of 0.10. VBI Vaccines has a 52-week low of $3.04 and a 52-week high of $5.17.
ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/14/vbi-vaccines-inc-vbiv-receives-average-rating-of-hold-from-analysts.html.
VBI Vaccines Company Profile
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.